Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer

Mia Petljak, Abby M. Green, John Maciejowski, Matthew D. Weitzman

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC)3 cytosine deaminase activity have been found in over half of cancer types, including some therapy-resistant and metastatic tumors. Driver mutations can occur in APOBEC3-favored sequence contexts, suggesting that mutagenesis by APOBEC3 enzymes may drive cancer evolution. The APOBEC3-mediated signatures are often detected in subclonal branches of tumor phylogenies and are acquired in cancer cell lines over long periods of time, indicating that APOBEC3 mutagenesis can be ongoing in cancer. Collectively, these and other observations have led to the proposal that APOBEC3 mutagenesis represents a disease-modifying process that could be inhibited to limit tumor heterogeneity, metastasis and drug resistance. However, critical aspects of APOBEC3 biology in cancer and in healthy tissues have not been clearly defined, limiting well-grounded predictions regarding the benefits of inhibiting APOBEC3 mutagenesis in different settings in cancer. We discuss the relevant mechanistic gaps and strategies to address them to investigate whether inhibiting APOBEC3 mutagenesis may confer clinical benefits in cancer.

Original languageEnglish
Pages (from-to)1599-1608
Number of pages10
JournalNature Genetics
Issue number11
StatePublished - Nov 2022


Dive into the research topics of 'Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer'. Together they form a unique fingerprint.

Cite this